BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study

Mitsuyoshi Urashima, Katharina Otani, Yasutaka Hasegawa, Taisuke Akutsu, Mitsuyoshi Urashima, Katharina Otani, Yasutaka Hasegawa, Taisuke Akutsu

Abstract

Ecological studies have suggested fewer COVID-19 morbidities and mortalities in Bacillus Calmette-Guérin (BCG)-vaccinated countries than BCG-non-vaccinated countries. However, these studies obtained data during the early phase of the pandemic and did not adjust for potential confounders, including PCR-test numbers per population (PCR-tests). Currently-more than four months after declaration of the pandemic-the BCG-hypothesis needs reexamining. An ecological study was conducted by obtaining data of 61 factors in 173 countries, including BCG vaccine coverage (%), using morbidity and mortality as outcomes, obtained from open resources. 'Urban population (%)' and 'insufficient physical activity (%)' in each country was positively associated with morbidity, but not mortality, after adjustment for PCR-tests. On the other hand, recent BCG vaccine coverage (%) was negatively associated with mortality, but not morbidity, even with adjustment for percentage of the population ≥ 60 years of age, morbidity, PCR-tests and other factors. The results of this study generated a hypothesis that a national BCG vaccination program seems to be associated with reduced mortality of COVID-19, although this needs to be further examined and proved by randomized clinical trials.

Keywords: BCG; Bacillus Calmette–Guérin; COVID-19; SARS-CoV-2; coronavirus disease 2019; ecological study; morbidity; mortality; urbanization; vaccination.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Histograms of morbidities and mortalities drawn as a normal density plot. (A) Morbidity per million; (B) mortality per million; (C) log10 transformed morbidity; and (D) log10 transformed mortality.
Figure 2
Figure 2
(A) Associations between morbidity, mortality and PCR-tests. Either Pearson’s correlation coefficient or Spearman’s rank correlation was applied to calculate rho; (B) associations between morbidity and risk factors were adjusted for PCR-tests per million population (log10); (C) associations between mortality and risk factors were adjusted for morbidity (log10) and PCR-tests (log10) per million population.
Figure 3
Figure 3
Scatter plot showing the association between PCR-test positivity and mortality. Mortality per million population and PCR-test positivity rates (%) on 17 July 2020 were transformed to the common logarithm (log10) in the graph. Since the variable of ‘PCR-test positivity (log10)’ showed a normal distribution, Pearson’s correlation coefficient was applied to calculate rho, to quantify the strength of the association. Countries that never had or stopped a national BCG vaccine program are indicated in red, while countries with current national BCG vaccine programs are indicated in black. Selected country names are shown using three-letter country codes.
Figure 4
Figure 4
Scatter plot showing the association between urban population and COVID-19 morbidity rates. COVID-19-related morbidity rates per million population on 17 July 2020 were transformed to the common logarithm (log10) in the graph. Since the variable of ‘urban population’ showed a non-normal distribution, Spearman’s rank correlation was applied to calculate rho, to quantify the strength of the association. Countries that had never had or that had stopped a national program of BCG vaccination are indicated in red, while countries that currently follow a national BCG vaccine program are indicated in black. Selected country names are shown using three-letter country codes.
Figure 5
Figure 5
Scatter plot showing the association between insufficient physical activity and COVID-19 morbidity rates.
Figure 6
Figure 6
Scatter plot showing the association between ≥60 years of age (%) of the population and mortality rate. Mortalities per million population on 17 July 2020 transformed to the common logarithm (log10) are presented in the graph. Since the variable of ‘percentage of population ≥ 60 years of age (%)’ showed a non-normal distribution, Spearman’s rank correlation was applied to calculate rho, to quantify the strength of the association. Countries that had never had or that had stopped their national BCG vaccine program are indicated in red, while countries that currently follow a national BCG vaccine program are indicated in black. Selected country names are shown using three-letter country codes.
Figure 7
Figure 7
Scatter plot showing the association between COVID-19-related mortality and BCG vaccine coverage. Mortalities per million population on 17 July 2020 are transformed to the common logarithm (log10) in the graph. Since the variable of ‘BCG vaccine coverage’ showed a non-normal distribution, Spearman’s rank correlation was applied to calculate rho, to quantify the strength of the association. Selected country names are shown using three-letter country codes.

References

    1. Murray C.J., Lopez A.D., Chin B., Feehan D., Hill K.H. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: A quantitative analysis. Lancet. 2006;368:2211–2218. doi: 10.1016/S0140-6736(06)69895-4.
    1. Price-Haywood E.G., Burton J., Fort D., Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. N. Engl. J. Med. 2020;382:2534–2543. doi: 10.1056/NEJMsa2011686.
    1. Patel A.P., Paranjpe M.D., Kathiresan N.P., Rivas M.A., Khera A.V. Race, Socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a National Biobank. medRxiv. 2020 doi: 10.1186/s12939-020-01227-y.
    1. Rentsch C.T., Kidwai-Khan F., Tate J.P., Park L.S., King J.T., Skanderson M., Hauser R.G., Schultze A., Jarvis C.I., Holodniy M., et al. Covid-19 by race and ethnicity: A national cohort study of 6 million United States veterans. medRxiv. 2020 doi: 10.1101/2020.05.12.20099135.
    1. Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. And the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;10:2052–2059. doi: 10.1001/jama.2020.6775.
    1. Grasselli G., Pesenti A., Cecconi M. Critical Care utilization for the COVID-19 outbreak in Lombardy, Italy: Early experience and forecast during an emergency response. JAMA. 2020;323:1545–1546. doi: 10.1001/jama.2020.4031.
    1. Lapostolle F., Goix L., Vianu I., Chanzy E., De Stefano C., Gorlicki J., Petrovic T., Adnet F. COVID-19 epidemic in the Seine-Saint-Denis Department of Greater Paris: One month and three waves for a tsunami. Eur. J. Emerg. Med. 2020;27:274–278. doi: 10.1097/MEJ.0000000000000723.
    1. Pereira I.G., Guerin J.M., Silva Júnior A.G., Garcia G.S., Piscitelli P., Miani A., Distante C., Gonçalves L.M.G. Forecasting Covid-19 dynamics in Brazil: A data driven approach. Int. J. Environ. Res. Public Health. 2020;17:5115. doi: 10.3390/ijerph17145115.
    1. Netea M.G., Joosten L.A., Latz E., Mills K.H., Natoli G., Stunnenberg H.G., O’Neill L.A., Xavier R.J. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352:6284. doi: 10.1126/science.aaf1098.
    1. Sharma A.R., Batra G., Kumar M., Mishra A., Singla R., Singh A., Singh R.S., Medhi B. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic? Allergol. Immunopathol. 2020 doi: 10.1016/j.aller.2020.05.002.
    1. Koti M., Morales A., Graham C.H., Siemens D.R. BCG vaccine and COVID-19: Implications for infection prophylaxis and cancer immunotherapy. J. Immunother. Cancer. 2020;8:e001119. doi: 10.1136/jitc-2020-001119.
    1. Ebina-Shibuya R., Horita N., Namkoong H., Kaneko T. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19. Respirology. 2020 doi: 10.1111/resp.13885.
    1. Curtis N., Sparrow A., Ghebreyesus T.A., Netea M.G. Considering BCG Vaccination to reduce the impact of COVID-19. Lancet. 2020;395:1545–1546. doi: 10.1016/S0140-6736(20)31025-4.
    1. Netea M.G., Giamarellos-Bourboulis E.J., Domínguez-Andrés J., Curtis N., van Crevel R., van de Veerdonk F.L., Bonten M. Trained immunity: A tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell. 2020;181:969–977. doi: 10.1016/j.cell.2020.04.042.
    1. O’Neill L.A.J., Netea M.G. BCG-induced trained immunity: Can it offer protection against COVID-19? Nat. Rev. Immunol. 2020;20:335–337. doi: 10.1038/s41577-020-0337-y.
    1. Ozdemir C., Kucuksezer U.C., Tamay Z.U. Is BCG vaccination affecting the spread and severity of COVID-19? Allergy. 2020 doi: 10.1111/all.14344.
    1. Gursel M., Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy. 2020;75:1815–1819. doi: 10.1111/all.14345.
    1. Miyasaka M. Is BCG vaccination causally related to reduced COVID-19 mortality? EMBO Mol. Med. 2020;12:e12661. doi: 10.15252/emmm.202012661.
    1. Coronavirus Update. [(accessed on 17 July 2020)]; Available online:
    1. World Population Clock. [(accessed on 22 May 2020)]; Available online:
    1. UN Data A World of Information. [(accessed on 17 July 2020)]; Available online:
    1. The BCG World Atlas. [(accessed on 20 May 2020)]; Available online: .
    1. The Global Health Observatory. [(accessed on 20 May 2020)]; Available online: .
    1. Kim J.H. Multicollinearity and misleading statistical results. Korean J. Anesthesiol. 2019;72:558–569. doi: 10.4097/kja.19087.
    1. Escobar L.E., Molina-Cruz A., Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) Proc. Natl. Acad. Sci. USA. 2020;117:202008410. doi: 10.1073/pnas.2008410117.
    1. Weng C.H., Saal A., Butt W.W., Bica N., Fisher J.Q., Tao J., Chan P.A. Bacillus Calmette-Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: A cohort study. Epidemiol. Infect. 2020;148:e140. doi: 10.1017/S0950268820001569.
    1. Klinger D., Blass I., Rappoport N., Linial M. Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: A multivariable analysis. Vaccines. 2020;8:378. doi: 10.3390/vaccines8030378.
    1. Arts R.J.W., Moorlag S.J.C.F.M., Novakovic B., Li Y., Wang S.Y., Oosting M., Kumar V., Xavier R.J., Wijmenga C., Joosten L.A.B., et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018;23:89–100. doi: 10.1016/j.chom.2017.12.010.
    1. Hisaka A., Yoshioka H., Hatakeyama H., Sato H., Onouchi Y., Anzai N. Global comparison of changes in the number of test-positive cases and deaths by coronavirus infection (COVID-19) in the world. J. Clin. Med. 2020;9:1904. doi: 10.3390/jcm9061904.
    1. Yates T., Razieh C., Zaccardi F., Davies M.J., Khunti K. Obesity and risk of COVID-19: Analysis of UK biobank. Prim. Care Diabetes. 2020 doi: 10.1016/j.pcd.2020.05.011.
    1. Ten Doesschate T., Moorlag S.J.C.F.M., van der Vaart T.W., Taks E., Debisarun P., Ten Oever J., Bleeker-Rovers C.P., Verhagen P.B., Lalmohamed A., Ter Heine R., et al. BCG-CORONA study team: Two randomized controlled trials of Bacillus Calmette-Guérin vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials. Trials. 2020;21:555. doi: 10.1186/s13063-020-04521-w.

Source: PubMed

3
Sottoscrivi